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Competitive interactionThe ORF3 protein of porcine circovirus type 2 (PCV2) causes apoptosis in virus-infected cells and is not
essential for virus replication. The ORF3 protein plays an important role in the pathogenesis of the PCV2
infection in mouse models and SPF piglets. The ORF3 protein interacts with the porcine homologue of Pirh2
(pPirh2), a p53-induced ubiquitin–protein E3 ligase, which regulates p53 ubiquitination. Here, we present
our study analyzing the details of the molecular interaction between these three factors. Our experiments, in
vitro and in vivo, show that ORF3 protein competes with p53 in binding to pPirh2. The amino acid residues
20 to 65 of the ORF3 protein are essential in this competitive interaction of ORF3 protein with pPirh2 over
p53. The interaction of ORF3 protein with pPirh2 also leads to an alteration in the physiological cellular
localization of pPirh2 and a signiﬁcant reduction in the stability of pPirh2. These events contribute to the
deregulation of p53 by pPirh2, leading to increased p53 levels and apoptosis of the infected cells.
© 2009 Elsevier Inc. All rights reserved.Introduction
Porcine circovirus (PCV) belongs to the Circoviridae family along
with other circoviruses of animals and birds. Two genotypes of PCV
have been recognized to date. The PK-15 cell-line-derived PCV is non-
pathogenic and is not associated with any disease and is designated
PCV1 (Allan et al., 1995; Tischer et al., 1986). On the other hand,
isolation of virus from tissues of diseased pigs led to identiﬁcation of
PCV2, which is the primary causative agent of postweaning multi-
systemic wasting syndrome (PMWS). The lesions associated with
PVC2 infection are lymphohistiocytic inﬁltrations to granulomatous
lymphadenitis, interstitial pneumonia, hepatitis, nephritis, myocar-
ditis, enteritis, and pancreatitis (Clark, 1997; Ellis et al., 1998;
Harding and Clark, 1997; Kiupel et al., 1998). Although controversial,
PCV2 is believed to cause immunosuppression by inducing apoptosis
in lymphocytes (Kiupel et al., 2005; Mandrioli et al., 2004; Resendes
et al., 2004; Shibahara et al., 2000). A novel protein encoded by open
reading frame 3 (ORF3) in the PCV2 genome was identiﬁed to induce
apoptosis in infected cells (Liu et al., 2005) and play an important role
in viral pathogenesis (Liu et al., 2006); furthermore, the PCV2 ORF3
protein speciﬁcally and directly interacts with an E3 ubiquitin ligase,eaning multisystemic wasting
ced RING H2 protein.
y Group, Temasek Lifesciences
earch Link, Singapore 117604.
ll rights reserved.porcine p53-induced RING H2 (pPirh2), which leads to the increase
in cellular p53 levels and thereby causes apoptosis of the infected
cells (Liu et al., 2007). Experimental and epidemiological evidence
indicates that PCV2-induced apoptosis in infected cells in pigs
contributes to the pathogenicity of the virus (An et al., 2008; Fenaux
et al., 2003; Karuppannan et al., 2009; Timmusk et al., 2008).
Experimental inoculation of piglets with a mutant PCV2 virus
deﬁcient in ORF3 protein expression (Karuppannan et al., 2009) or
a chimeric PCV2 virus with the ORF2 genomic region of PCV2 and the
ORF1 genomic region, with the nested ORF3, from PCV1 (Fenaux et
al., 2003) is non-pathogenic to the inoculated piglets. It should be
noted that ORF2 and ORF3 of PCV1 and PCV2 are signiﬁcantly
dissimilar, whereas the ORF1 of the two virus genotypes is more than
85% identical at the amino acid level.
The tumor suppressor p53 protein is activated and induced by
multiple stresses like DNA damage, oncogenic transformation,
hypoxia, replication stress, etc. (Horn and Vousden, 2007; Kastan,
2007). The activated p53 exerts its tumor suppressor function by
inhibiting cell cycling or promoting apoptosis in abnormal cells (Horn
and Vousden, 2007; Riley et al., 2008). The tight regulation of p53
level and its activities, by regulation of its transcription, post-
translational modiﬁcation, protein stability, and subcellular localiza-
tion are crucial for maintaining normal cell growth and preventing
tumorigenesis (Haupt, 2004; Levine, 1997). The regulation of p53
through post-translational modiﬁcations includes phosphorylation
and acetylation (Appella and Anderson, 2001; Brooks and Gu, 2003).
Regulation of subcellular localization of p53 leads to translocation of
p53 from cytoplasm to the nucleus where it acts as a transcriptional
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Qian et al., 2002; Riley et al., 2008). The stability of the p53 is
regulated mainly by the ubiquitin–proteasome system (Haupt et al.,
1997; Honda et al., 1997; Kubbutat et al., 1997). Several studies have
shown that Mdm2, Pirh2, and CopI (Corcoran et al., 2004; Dornan et
al., 2004; Fang et al., 2000; Honda and Yasuda, 2000; Kubbutat et al.,
1997) are the important E3 ubiquitin ligases regulating p53. Among
them, Pirh2 (also known as Rchy1) is a ubiquitin–protein E3 ligase,
which interacts physically with the tumor suppressor p53 and
promotes polyubiquitination of p53 and mediates the cytoplasmic
proteasomal degradation of p53 (Leng et al., 2003). Pirh2 is itself a
p53-inducible gene product and the expression of Pirh2 is tightly
regulated by the p53-Pirh2 autoregulatory feedback loop, which also
facilitates the tight regulation of p53 stability and tumor suppression
(Leng et al., 2003).
The structure of Pirh2 and the structural basis of its interaction
with p53 have been recently elucidated, showing that Pirh2
preferentially ubiquitinates the transcriptionally active form of p53
(Sheng et al., 2008). Furthermore, the Pirh2 protein is believed to
have its three domains, the N-terminal domain, RING domain, and
the C-terminal domain, which fold independently of each other,
arranged in modular fashion and they do not interact with each other
(Sheng et al., 2008). The interaction between PCV2 ORF3 protein and
pPirh2 has been shown to be critical in the molecular pathogenesis of
the virus (Karuppannan et al., 2009; Liu et al., 2005, 2006, 2007).
Measles virus has also been shown to manipulate the subcellular
localization of human Pirh2 (hPirh2) by redistributing the protein to
cytoplasm and affecting the stability of hPirh2 (Chen et al., 2005). Our
previous studies have indicated that the PCV2 ORF3 protein binds to
the pPirh2, leading to the decrease of cellular pPirh2 levels (Liu et al.,
2007). Here, we further examine the molecular nature of the
interaction of ORF3 protein and p53 with pPirh2 in vitro and in
vivo. We have mapped the minimal interaction domain, comprising
of amino acid residues 20 to 65 in the ORF3 protein, as essential in
competitive interaction between ORF3 protein and p53 in binding to
pPirh2 and contributing to p53 deregulation. This speciﬁc interaction
plays an important role in virus-induced apoptosis of the infected
cells and the viral pathogenesis.Fig. 1. The ORF3 protein directly binds to pPirh2 and prevents p53 from binding to pPirh2 in
amount ofMBP-tagged p53 (10 μg) and increasing amounts of MBP-tagged ORF3 (0, 5, 10, 15
of MBP-ORF3. After washing the beads, MBP-tagged proteins bound to the beads were detec
antibody.Results
The ORF3 protein prevents p53 from binding pPirh2 in vitro and in vivo
The binding of ORF3 protein to the p53 interacting domain of
pPirh2 was previously identiﬁed by a yeast two-hybrid screen (Liu et
al., 2007). Further yeast two-hybrid experiments with mutated ORF3
protein and the full-length pPirh2 identiﬁed the amino acid residues
20 to 75 of ORF3 protein to be necessary for the interaction between
the two proteins (Karuppannan et al., 2009). To further characterize
the nature and effect of this interaction, a competitive pull down assay
was carried out using puriﬁed recombinant proteins. Brieﬂy, 10 μg of
GST-Pirh2 was incubated with a constant amount of MBP-p53 (10 μg)
and increasing amounts of MBP-ORF3 (0-25 μg). The GST-Pirh2 was
then pulled down and the bound MBP-tagged p53 and ORF3 were
visualized by Western blotting. As shown in Fig. 1, the amount of p53
bound to GST-Pirh2 decreasedwith an increase in the amount of ORF3
protein in the mixture, indicating that the ORF3 protein prevents p53
from binding to pPirh2 in vitro. At equal protein concentrations of
ORF3 and p53, more ORF3 bound to the pPirh2.
To further determine the relative binding capacities of pPirh2 to
ORF3 protein and p53 in vivo, H1299 cells, which do not express p53,
were cotransfected with the expression plasmids for ORF3-GFP, p53-
GFP, and Myc-Pirh2. The transfected cells were lysed 36 h post-
transfection and co-immunoprecipitation assay was performed with
anti-myc antibody. Western blotting against the common GFP epitope
tag was performed to compare the expression levels of ORF3 protein
and p53 in the lysates and to estimate the comparative amount of
protein co-immunoprecipitating with pPirh2. When ORF3-GFP and
p53-GFP were expressed at similar levels, Myc-Pirh2 co-precipitated
signiﬁcantly more ORF3 protein than p53 (Fig. 2A). However, when
only p53-GFP and Myc-Pirh2 expression plasmids were transfected in
H1299 cells, the amount of p53-GFP co-precipitating with Myc-Pirh2
was higher than in the presence of ORF3 protein (Fig. 2A) and was
comparable to the level of expression in the lysate (Fig. 2B). To further
conﬁrm the observations, reciprocal co-immunoprecipitation experi-
ments were performed with anti-ORF3 and anti-p53 polyclonal
antibodies. Similar amounts of ORF3-GFP and p53-GFP were pulledvitro. Glutathione beads coated with 10 μg of GST-Pirh2 were incubated with a constant
, 20, and 25 μg in lanes 1 to 6, respectively). Lane 7 is a control without MBP-p53 and 5 μg
ted by immunoblotting with an anti-MBP antibody or anti-p53 or anti-ORF3 or anti-GST
Fig. 2. Relative interaction of pPirh2 to p53 and ORF3 protein, in vivo. (A) H1299 cells were transfected with Myc-Pirh2 and p53-GFP in the presence or absence of ORF3-GFP. Anti-
Myc immunoprecipitate was blotted with anti-GFP antibody to detect the relative amounts of co-precipitated ORF3-GFP and p53-GFP. Comparison of the ratio of ORF3-GFP to p53-
GFP in the lysate and the immunoprecipitate suggests stronger binding of Pirh2 to ORF3 protein than p53 (lane 5). Pirh2 co-precipitates more p53 in the absence of ORF3 protein
(lane 3). (B) H1299 cells were transfected with Myc-Pirh2 and p53-GFP in the presence or absence of ORF3-GFP. Anti-GFP immunoblot of lysates (same experiment as depicted in
Fig. 5A) from H1299 cells transfected with the three constructs Myc-Pirh2, p53-GFP, and ORF3-GFP, as indicated. (C) ORF3 interferes with the binding of Pirh2 to p53. Co-
immunoprecipitation experiment was performed by using cell lysate fromH1299 cells transfected with expression plasmids for Myc-Pirh2, p53-GFP, and ORF3-GFP. Thirty-six hours
after transfection, the cell lysate was immunoprecipitated with anti-ORF3 polyclonal antibodies and anti-p53 polyclonal antibodies, in lane 1 and lane 2, respectively, and
immunoblotted with anti-Myc or anti-GFP antibodies.
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antibodies co-precipitated more Myc-Pirh2 than anti-p53 antibodies
(Fig. 2C). This shows that ORF3 competeswith p53 in binding to pPirh2,
when expressed at similar levels. Taken together the pull down assay
and the immunoprecipitation assays suggest that ORF3 protein
competes with p53 in binding to pPirh2, in vitro and in vivo, and
modulates pPirh2–p53 complex formation.
ORF3 protein alters the subcellular localization of pPirh2
In the caseof proteins targeted forubiquitin-dependentdegradation,
subcellular localization is a factor that can regulate protein stability. Ithas been previously demonstrated that Pirh2 subcellular localization
could be critical in its regulation and stability (Logan et al., 2004). The
Pirh2 mediates the polyubiquitination of the tetrameric, transcription-
ally active, p53 in the nucleus and leads to the p53 export to the
cytoplasm and subsequent proteasomal degradation (Sheng et al.,
2008). In an attempt to explain the mechanism by which ORF3 protein
could interfere with the function of pPirh2 in regulating p53 protein
stability, the subcellular localization of pPirh2 was examined in the
presence of ORF3 protein, in H1299 cells. pPirh2 was found in the
nucleus after transfection in H1299 cells (Fig. 3A). Interestingly, co-
transfection of pPirh2 with ORF3 protein resulted in signiﬁcant accu-
mulation of pPirh2 in the cytoplasm (Fig. 3B). This suggests the inter-
Fig. 3. ORF3 protein alters the localization of pPirh2. H1299 cells were cotransfected with the expression plasmids for Myc-tagged pPirh2 alone (A) or in combination with
expression plasmids for GFP-tagged ORF3 (B). At 36 h post-transfection, cells were ﬁxed and immunostained with an anti-Myc antibody.
Fig. 4. ORF3 protein decreases the stability of Pirh2. (A and B) H1299 cells were transfected with expression plasmids for Myc-Pirh2 alone (A) or in combination with ORF3-GFP (B).
The stability of Pirh2 was estimated 24 h post-transfection by using cycloheximide (50 μg/ml). The cell lysates obtained at different time points after cycloheximide treatments were
analyzed for Pirh2 levels by Western blotting. (C) Estimation of Myc-Pirh2 protein levels at different time points after cycloheximide treatment in H1299 cells transfected with
expression plasmids for Myc-Pirh2 alone (solid line) or in combination with ORF3-GFP (dotted line). The protein levels were estimated by Western blotting with infrared dye (IR
680)-conjugated secondary antibody followed by scanning with an infrared scanner. The normalized Myc-Pirh2 protein levels are expressed as a percent of the initial level before
cycloheximide treatment.
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Fig. 5. (A) Schematic diagram of ORF3 protein and its deletion mutants. (B) ORF3 protein and its deletion mutants differ in their ability to induce loss of cell viability. PK-15 cells and
H1299 were transfected with ORF3-GFP or its deletion mutants and after 36 h the viability of the cells was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide tetrazole) assay. Cells transfected with GFP expression plasmids carrying no inserts were used as a control and nontransfectd PK-15 cells or H1299 cells were treated as
100% viable cells. (C) PK-15 cells and H1299 were transfected with ORF3-GFP or its deletion mutants, and after 36 h, the level of apoptotic cells was measured by ﬂowcytometric
analysis. At least 10,000 events were acquired and the percent of cells with sub G0/G1 level of DNA content were estimated.
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6 A.K. Karuppannan et al. / Virology 398 (2010) 1–11action ofORF3protein,which localizes to the cytoplasm,withpPirh2. The
above observations suggest that in the presence of ORF3 protein, pPirh2
would not be available to down-regulate the p53 levels in the nucleus.
ORF3 protein increases the turnover of pPirh2
The stability of Pirh2 is affected by many proteins (Chen et al.,
2005; Duan et al., 2007; Logan et al., 2004; Zheng et al., 2007). Ourprevious observations showed a decrease in the level of pPirh2
protein during PCV2 infection (Liu et al., 2007). Here, we estimated
the turnover of the pPirh2 protein in the presence or absence of ORF3
protein, in H1299 cells. Expression plasmid encoding Myc-Pirh2 was
transfected in H1299 cells, alone or in combination with expression
plasmid coding for ORF3-GFP and the turnover of the pPirh2 was
measured using protein synthesis inhibitor cycloheximide. The
quantities of plasmids used for the transfection were kept minimal
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and translation apparatus of the transfected cells. The result showed
that pPirh2, when overexpressed alone, was detectable for about 5 h
after cycloheximide treatment (Fig. 4A). However, the pPirh2 ex-
pressed with ORF3 protein was not detectable after 2 h of
cycloheximide treatment (Fig. 4B). In order to quantify the levels of
pPirh2 after cycloheximide treatment, Western blotting was per-
formed followed by protein visualization and quantiﬁcation with
infrared dye-conjugated secondary antibody using a sensitive infrared
scanner. The pPirh2 levels, at 2 h after cycloheximide treatment, were
twofold less in the presence of ORF3 compared to the pPirh2 alone
(Fig. 4C). The results again indicated that the ORF3 protein mediates
the faster turnover of pPirh2.
Mapping of the minimal domain of ORF3 protein that binds with pPirh2
To identify the regions on ORF3 protein involved in interaction
with pPirh2, eukaryotic expression plasmids of full-length ORF3
protein tagged with GFP or its deletion mutants (Fig. 5A) were trans-
fected into PK-15 cells. A MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, a tetrazole) assay was performed to
measure the relative numbers of viable cells at 36 h after transfection
of wild-type ORF3 and the mutant ORF3 constructs in PK-15 cells. In
this assay MTT is reduced to purple formazan by enzymes in the living
cells. The results showed that PK-15 cells transfected with ORF3-20–
50 GFP and ORF3-35–65 GFP showed signiﬁcantly more number of
viable cells compared with cells transfected with wild-type ORF3 and
other mutants (Fig. 5B). We assumed that the ORF3 deletion mutants
20–50 and 35–65 induce fewer cells to become apoptotic than that of
wild-type ORF3 or other ORF3 deletion mutants owing to their loss of
the ability to interact with pPirh2. To conﬁrm this, the level of
apoptosis in the PK-15 cells transfected with different deletion
construct of ORF3 was analyzed by ﬂow cytometry. The results (Fig.
5C) showed that the ORF3 deletion mutants 20–50 and 35–65 did not
induce apoptosis in the transfected cells and were comparable to the
vector control expressing GFP only. Interestingly, when H1299 cells,
lacking endogenous p53, were transfected with the different
constructs of ORF3, the viability of the cells was not reduced to the
extent observed in similarly transfected PK-15 cells (Fig. 5B) and
further there was no signiﬁcant difference in the viability of the cells
transfected with the different ORF3-GFP constructs.
To further investigate the interaction between ORF3 mutants and
pPirh2, an in vitro pull down assay was carried out using puriﬁed
recombinant MBP-tagged ORF3 or MBP-tagged ORF3 deletion
mutants. MBP-tagged ORF3 protein or MBP-tagged ORF3 deletion
mutants were incubated with glutathione beads coated with GST-
Pirh2 in an in vitro binding assay. After extensive washing, the protein
bound to beads was analyzed by immunoblotting with an anti-MBP
antibody or anti-GST antibody (Fig. 6A). The results further demon-
strated that the ORF3 protein with deletions in the amino acid
residues 20–50 and 35–65 does not interact with pPirh2 as efﬁciently
as wild-type ORF3 protein or other ORF3 deletion mutants, whichFig. 6. (A) Interaction between the ORF3 protein and its deletion mutants with Pirh2 in vitro.
with GST-Pirh2, and after extensive washing, the proteins bound to the beads were analyze
MBP-ORF3; 3, MBP-ORF3-20; 4, MBP-ORF3-20-50; 5, MBP-ORF3-35-65; 6, MBP-ORF3-50-80
sequence does not hinder the interaction between Pirh2 and p53. H1299 cells were transfe
amino acids 30–60. The total lysate and Myc-Pirh2 immunoprecipitate from the lysate were
co-precipitated ORF3-GFP and p53-GFP. (C) ORF3 with deletion in its minimal binding sequ
with the expression plasmids for Myc-Pirh2 in combination with expression plasmid for OR
and immunostained with an anti-Myc antibody. (D) ORF3 protein with deletion in its minim
with expression plasmids for Myc-Pirh2 in combination with ORF3-GFP harboring a deletio
using cycloheximide (50 μg/ml). The cell lysates obtained at different time points after cycloh
Myc-Pirh2 protein levels at different time points after cycloheximide treatment in H1299
deletion of amino acids 30–60. The protein levels were estimated by Western blotting with
secondary antibody and subsequent scanning by an infrared scanner. The normalized Myc-
treatment.suggested that the region containing the 20th to 65th amino acid
residues could be important in the interaction between pPirh2 and
p53. For further conﬁrmation of the lack of interaction, co-immuno-
precipitation studies were performed in H1299 cells cotransfected
with Myc-Pirh2, p53-GFP, and ORF3-GFP with deletion of amino acids
30 to 60. The Myc-Pirh2 co-immunoprecipitated p53-GFP but did not
co-immunoprecipitate the ORF3-GFP deletion mutant (Fig. 6B),
showing that the deleted regions were necessary for the interaction
between pPirh2 and ORF3.We next examined if the lack of interaction
between the ORF3 30-60 and pPirh2 had any effect on the localization
and stability of pPirh2. Immunoﬂuorescence assay revealed that the
ORF3 deletion mutant 30–60 did not alter the localization of the
pPirh2 from the nucleus to the cytoplasm (Fig. 6C). In addition, the
turnover of the pPirh2 co-expressed with ORF3 deletion mutant 30–
60 (Figs. 6D and E), in H1299 cells, were similar to that of pPirh2
expressed in the absence of ORF3. These results illuminated the fact
that an interaction between ORF3 and pPirh2 is necessary for the
altered cellular fate of pPirh2.
Interaction of ORF3 protein with pPirh2 up-regulates cellular p53 levels
The observation of interaction between the ORF3 protein or its
deletion mutants and pPirh2 prompted an examination to determine
whether the ORF3 deletion mutation proteins affected the p53 level
and its apoptosis-inducing function. Since the ORF3 deletion mutants
20–50 and 35–65 cannot induce apoptosis in cells markedly as shown
above (Fig. 5B), these two deletion mutants probably have no effect
on the expression of p53 as compared with wild-type ORF3 or other
ORF3 deletion mutants. The expression of p53 in PK-15 cells
transfected with ORF3-GFP or ORF3-GFP deletion mutant expression
constructs was analyzed by a Western blotting assay. The results
showed that p53 was expressed in higher level after transfection with
different ORF3 constructs compared with normal PK-15 cells, but p53
expression in cells transfected with ORF3-20–50 GFP and ORF3-35–65
GFPwere less than that of ORF3 full-length construct or other deletion
mutants (Fig. 7). These results illuminated that ORF3 20–50 and 35–
65 deletion mutants do not signiﬁcantly affect the expression level of
p53 because of their lack of interaction with pPirh2.
ORF3 interferes with the in vitro ubiquitination of p53
The interaction of ORF3 with Pirh2 could potentially interfere with
the E3 ubiquitin ligase function of Pirh2. To examine this, an in vitro
ubiquitination assay was performed. The assay was performed with
Pirh2 as an E3 ubiquitin ligase, GST-p53 as the target protein, His-
tagged ubiquitin, and E1 and E2 ubiquitin ligases as described in the
methods. The GST-p53 was pulled down at the end of the assay and
analyzed by Western blotting. The His-tagged ubiquitin was cova-
lently conjugated to p53 in the absence of ORF3 (Fig. 8). However, in
the presence of ORF3, the ubiquitination of p53 was almost com-
pletely inhibited. The results of this in vitro ubiquitination assay
indicate that ORF3 interferes with the ubiquitination of p53 by Pirh2.MBP, MBP-ORF3, or its deletion mutants were incubated with glutathione beads coated
d using immunoblotting with an anti-MBP antibody or GST antibody. (Lane 1, MBP; 2,
; 7, MBP-ORF3-65-95; 6, MBP-ORF3-80). (B) ORF3 with deletion in the minimal binding
cted with Myc-Pirh2 and p53-GFP in the presence of ORF3-GFP harboring a deletion of
analyzed by immunoblotting with anti-GFP antibody to detect the relative amounts of
ence does not alter the subcellular localization of Pirh2. H1299 cells were cotransfected
F3-GFP with a deletion of amino acids 30–60. At 36 h post-transfection, cells were ﬁxed
al binding sequence does not alter the stability of Pirh2. H1299 cells were transfected
n of amino acids 30–60. The stability of Pirh2 was estimated 24 h post-transfection by
eximide treatment were analyzed for Pirh2 levels byWestern blotting. (E) Estimation of
cells transfected with expression plasmids for Myc-Pirh2 and ORF3-GFP harboring a
anti-GFP or anti-actin primary antibodies followed by infrared dye (IR 680)-conjugated
Pirh2 protein levels are expressed as a percent of the initial level before cycloheximide
Fig. 7. Detection of endogenous p53 after transfection with ORF3-GFP and its deletion mutants in PK-15 cells. The expression of p53 was estimated, 24 h after transfection with ORF3
or its deletion mutants, by Western blotting assay for detecting the levels of p53 by using guinea pig anti-p53 antibody. Anti-actin immunoblotting was used for protein loading
control.
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stabilization of p53 in vivo.
Discussion
The role of ORF3 protein in the induction of apoptosis in PCV2-
infected cells has been previously demonstrated (Liu et al., 2005).
Furthermore, the ORF3 protein is also important in determining the
pathogenicity of the PCV2 at the organismal level in mice and piglets
(An et al., 2008; Fenaux et al., 2003; Karuppannan et al., 2009; Liu et
al., 2006). A recent report has highlighted the pathogenic role of ORF3
by overexpressing the protein in mice, leading to severe inﬂammatory
reactions or mortality (An et al., 2008). Here we show that PCV2 ORF3
protein and p53 competitively interact with pPirh2 and that the ORF3Fig. 8. In vitro assay for ubiquitination of p53. The in vitro ubiquitination of GST-p53
was analyzed in the presence or absence of ORF3, with Pirh2 as the E3 ubiquitin ligase
and His-tagged ubiquitin. The GST-p53 was puriﬁed with glutathione beads and
analyzed by Western blotting with anti-His or anti-p53 antibodies.protein is able to prevent the interaction between pPirh2 and p53
(Figs. 1 and 2) both in vitro and in vivo. In addition, our data strongly
reveal that the fragment comprising the amino acid residues from 20
to 65 residues of the ORF3 protein is essential (Figs. 5–7) in the
competitive binding of ORF3 protein to pPirh2 over p53. The
interaction of ORF3 to pPirh2, sequesters pPirh2 in the cytoplasm
(Fig. 3), and prevents its physiological localization to the nucleus,
where it functions to polyubiquitinate p53, leading to its cytoplasmic
export and degradation. The interaction of pPirh2 to ORF3 protein
further leads to the decreased stability of the pPirh2 (Fig. 4). Thus the
sequestration and destabilization of pPirh2 by ORF3 protein lead to
the increase in cellular p53 levels (Fig. 7), leading to apoptosis of the
cells. Furthermore, the ORF3 interferes with the E3 ubiquitin ligase
function of Pirh2 to ubiquitinate p53 in an in vitro ubiquitination
assay (Fig. 8). This indicates that the interaction of ORF3 and Pirh2
leads to the deregulation of the p53 degradation and its stabilization.
The effect of the interaction between ORF3 and pPirh2 is reiterated by
the lack of altered localization or increased turnover of the pPirh2 by
the ORF3 mutant 30–60, lacking the minimal interaction domain
(Figs. 6C, D, and E).
Together with the results obtained by Liu et al. (2007), the data
presented here suggest that ORF3 protein increases cellular p53 level
and favors the induction of apoptosis by competitive binding to
pPirh2, over p53, and the cytoplasmic sequestration of pPirh2. First,
the competitive binding of ORF3 protein to pPirh2 could abrogate the
E3 ubiquitin ligase function of pPirh2 on p53 and indirectly lead to the
accumulation of p53 (Figs. 7 and 8). The cellular accumulation of Pirh2
regulated proteins, in the absence of Pirh2, has been previously
observed (Hattori et al., 2007). The pPirh2-mediated increase in p53
protein can lead to the increased accumulation of p53 in the nucleus
and the increased transcriptional activity mediated by p53 and the
increased cellular susceptibility to apoptosis. Second, ORF3 protein
could induce post-translational modiﬁcations of pPirh2, which may
further cause conformational changes that make pPirh2 less func-
tional ormore susceptible to degradation. Our observations here show
that the stability of pPirh2 is signiﬁcantly reduced in the presence of
ORF3 protein. This observation is in concurrence with our previous
observation that pPirh2 is reduced in PCV2-infected cells (Liu et al.,
2007). Studies on the physiological regulation of Pirh2 are few. The
CaMII kinase (calmodulin-dependent kinase II) phosphorylates Pirh2
and the phosphorylation of Pirh2 impairs its p53 E3 ubiquitin ligase
function (Duan et al., 2007). Furthermore, the phosphorylation of
Pirh2 impairs its stability (Duan et al., 2007). Various cellular factors
like TIP60, PLAGL2 are also known to increase the stability of Pirh2
(Logan et al., 2004; Zheng et al., 2007). The degradation of hPirh2 is
thought to depend on its polyubiquitination and also on the presence
of an intact RING domain (Logan et al., 2004). A histone acetylase
TIP60, by its interaction, is able to stabilize polyubiquitinated Pirh2.
However, the acetylase activity of TIP60 is dispensable for this effect
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protein, the measles virus phosphoprotein (P protein), is known to
interact with and stabilize the hPirh2 by preventing its ubiquitination
(Chen et al., 2005). The ORF3 protein negatively affects the pPirh2
stability by a yet unknown mechanism. The Pirh2 is also known to
regulate the stability of many other proteins apart from p53; notable
among them are p27kip1, HDAC1, epsilon COP, and signal recognition
particle subunit beta (Abe et al., 2008; Hattori et al., 2007; Logan et al.,
2006; Maruyama et al., 2008). The interaction of ORF3 protein with
pPirh2 could also affect cellularmechanisms other than p53-regulated
cell survival. This was examined in the H1299 cells, which lack endo-
genous p53. Our observations upon overexpression of ORF3 protein in
H1299 cells, lacking p53, indicate (Fig. 5B) that p53-mediated
apoptosis is the foremost effect of ORF3 protein on the cellular
homeostasis. In summary, the data presented here demonstrate a link
between the competitive interaction of ORF3 protein with pPirh2 and
the regulation of p53-mediated apoptosis, which is one of the
important molecular mechanisms involved in PCV2 pathogenicity.
Pirh2 is known to be overexpressed in lung cancer cells of humans,
mice lung cancer models, and prostate cancer in humans (Duan et al.,
2004; Logan et al., 2006; Sheng et al., 2008). The role of Pirh2 in
promoting tumor formation is thought to be independent of Mdm2,
another important E3 ligase regulating the levels of p53 (Duan et al.,
2004; Sheng et al., 2008). Targeting the p53-Pirh2 interface is an
attractive approach to discover agents that activate p53 in tumors. In
one instance, the targeting of Pirh2 by siRNA along with siRNA
targeting the oncogenic E6 protein of human papillomavirus, in Hela
cervical cancer cells, enabled the sustained restoration of activated
p53 (Koivusalo et al., 2006). Strategies of disruption of the p53–Pirh2
interaction have a novel potential as new anticancer agents as the
binding sites of Pirh2 and Mdm2 on p53 are distinct (Sheng et al.,
2008). The ORF3 protein is a naturally evolved molecule (Timmusk et
al., 2008), which binds to the p53-interacting domain of Pirh2 (Liu et
al., 2007). The ORF3 efﬁciently disrupts the p53 homeostasis by
interacting with Pirh2, through its amino acid residues 20 to 65, and
favors apoptosis. Based on our results, we speculate that the inhibition
of p53–Pirh2 interaction in cells, with exogenous ORF3 protein or
synthetic peptide molecules of ORF3 protein (such as fragment from
the 20th to 65th amino acid residues) should lead to both the nuclear
accumulation and the activation of p53, increasing the propensity of
the cells towards apoptosis. The ORF3 protein-mediated inhibition of
the p53–Pirh2 interaction might be an attractive new way for an anti-
virus or anticancer agent that could be used to activate wild-type p53
in target cells. Further investigation of the dynamics behind the
evolution of ORF3 as an apoptosis inducing gene would be interesting.
Materials and methods
Cell culture and transient transfections
The PK-15 cells are of porcine origin and free of PCV1 contami-
nation (Liu et al., 2005). The cells were maintained in minimal
essential medium supplemented with 5% heat-inactivated fetal
bovine serum (FBS), 5% L-glutamine, 100 U/ml of penicillin G, and
100 μl/ml streptomycin at 37 °C in a humidiﬁed 5% CO2 incubator. The
H1299 cells of human origin lack endogenous p53 expression (ATCC
CRL 5803). The H1299 cells were maintained in RPMI 1640 media
supplemented with 5% heat-inactivated fetal bovine serum (FBS),
100 U/ml of penicillin G, and 100 μl/ml streptomycin at 37 °C in a
humidiﬁed 5% CO2 incubator. All transient transfections were
performed using Transfectin reagent (Biorad).
Plasmids and recombinant proteins
The recombinant protein expression plasmids encoding recombi-
nant proteins MBP-p53, MBP-ORF3 were made by cloning the full-length PCR products of p53 and ORF3 genes in pMAL- c4×vector
(New England Biolabs). MBP-ORF3 deletion expression plasmidswere
made by cloning the deletion constructs of ORF3 (Fig. 5A), made by
PCR assembly, in the pMAL-c4X vector. The primers used for making
the ORF3 deletion constructs are available upon request. The
expression plasmids were transformed into Escherichia coli K12 TB1
cells for the expression of the proteins. TheMBP-tagged proteins were
puriﬁed by afﬁnity chromatography with amylose resin (New
England Biolabs) packed columns according to the manufacturer's
instructions. The GST-Pirh2 recombinant protein expression plasmid
was made by cloning the full-length pPirh2 in the pGEX 4T1 vector
(GE Life Sciences) and the expression plasmid was transformed into E.
coli BL21 cells. The recombinant protein was puriﬁed by afﬁnity
chromatography using GSTrap FF Columns (GE Life Sciences).
The eukaryotic expression plasmids for p53-GFP and ORF3-GFP
were constructed by cloning the full-length PCR products in pEGFP N1
vector (Clontech). ORF3-GFP deletion eukaryotic expression plasmids
were made by cloning the deletion constructs of ORF3 (Fig. 5A), made
by PCR assembly, in the pEGFP N1 vector. TheMyc-Pirh2 was made by
cloning full-length pPirh2 in the pCMV Myc vector.
Binding assays
The in vitro binding assay was adapted from Leng et al. (2003).
Brieﬂy, glutathione beads alone, as negative control, or glutathione
beads coated with 10 μg of GST-Pirh2 in binding buffer (100mMNaCl,
20 mM Tris–HCl [pH 8.0], 0.5% NP-40, 1 mM EDTA, 1 mM EGTA) were
incubated, in separate reactions, with a constant amount of MBP-p53
(10 μg) in combination with increasing amounts (0–25 μg) of MBP-
ORF3 or deletion constructs of MBP-ORF3, overnight at 4 °C. The
glutathione beads were then pelleted down and proteins bound to the
beads were subsequently washed four times with the binding buffer.
Proteins bound to the glutathione beads were eluted with SDS sample
buffer and subjected to 12% SDS–polyacrylamide gel electrophoresis
(PAGE) followed by electro-transfer to a nitrocellulose membrane.
Twomicrograms of total protein was loaded in each lane. The blot was
incubated with a rabbit anti-MBP antibody (Clontech, 1:10,000) or a
polyclonal guinea pig anti-p53 antibody (1:500) or an anti-ORF3
polyclonal-antibody (1:1000) or a goat anti-GST antibody (Clontech,
1:500), and then incubated with the appropriate secondary antibody
coupled with horseradish peroxidase, namely goat anti-rabbit IgG
(1:2000; Amersham) or rabbit anti-guinea pig IgG (1:2000; Amer-
sham) or rabbit anti-mouse IgG (1:2000; Amersham) or rabbit anti-
goat IgG (1:2000; Amersham) and visualized with the ECL plus
detection system (Amersham) or Supersignal chemiluminescence
system (Pierce). Appropriate control experiments were performed
with MBP and GST proteins, without any fusion proteins attached, to
rule out non-speciﬁc interaction of MBP with Pirh2 and GST with
ORF3 or p53 (data not shown).
Co-immunoprecipitation assays
H1299 cells were cotransfected with the expression plasmids for
ORF3-GFP, p53-GFP, and Myc-Pirh2. At 36 h post-transfection, cell
extracts were prepared and used for co-immunoprecipitation assay
either using a commercial kit according to the manufacturer's
protocol (Profound Myc CoIP kit, Pierce) or using polyclonal anti-
p53 and polyclonal anti-ORF3 antibodies followed by the pull down of
the antibody antigen complex using protein A sepharose beads
(Sigma). Brieﬂy, 100 μl of M-PER lysis buffer (Pierce) supplemented
with Complete mini protease inhibitor (Roche) and 1 mM of sodium
orthovanadate was used to prepare the cell extract from one 35-mm-
diameter cell culture dish, transfected with the appropriate plasmids.
Lysates from three dishes were pooled and 300 μl of the lysate was
used for the immunoprecipitation. The precipitated proteins were
eluted with 30 μl elution buffer. The lysates and the immunopreci-
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epitope tag using a monoclonal anti GFP antibody. The blots were also
probed with anti-Myc monoclonal antibody, anti-p53 polyclonal
antibodies, and anti-ORF3 polyclonal antibodies.
Immunoﬂuorescence assays
H1299 cells seeded on a coverslip were cotransfected with the
expression plasmids for fusion proteins Myc-Pirh2 and ORF3-GFP. At
36 h post-transfection, cells were ﬁxed in 4% paraformaldehyde for
30 min and permeabilized with 0.1% Triton X-100 for 15 min at room
temperature. Cells were incubated with a mouse monoclonal anti-
Myc antibody (BD Pharmingen), at 37 °C for 1 h. After washing, cells
were incubated with Alexa 560 coupled anti-mouse immunoglobulin
secondary antibody (Invitrogen) for 1 h. The cells were then washed,
mounted with VECTASHIELD mounting medium (Vector), and
examined with a Zeiss LSM Meta 510 confocal microscope.
Estimation of protein turnover rates
The assay to determine the stability of pPirh2 was performed in
H1299 cells in 35-mm-diameter plates transfected with 100 ng Myc-
Pirh2 expression plasmid alone or in combination with 100 ng of
ORF3-GFP expression plasmid. Twenty-four hours after transfection,
cells were treated with 50 μg/ml of cycloheximide (Calbiochem) for
different lengths of time before the cells were lysed with M-PER cell
lysis buffer (Pierce) supplemented with complete mini protease
inhibitor cocktail (Pierce) and 1 mM of sodium orthovanadate. Cell
lysates were analyzed by immunoblotting with anti-Myc antibody
followed by HRP-conjugated anti-mouse secondary antibody to detect
Pirh2 levels. Immunoblotting with anti-GFP antibody was performed
as a loading control. The protein levels were quantiﬁed by immuno-
blotting with anti-Myc antibody or anti-actin antibody followed by an
infrared dye (IR680)-conjugated secondary antibody (Li-Cor). The
protein band intensities were measured by Li-Cor Odyssey infrared
scanner. TheMyc-Pirh2 protein levelswere normalizedwith reference
to actin levels in the lysate and are expressed as a percent of the initial
level of Myc-Pirh2 protein before cycloheximide treatment.
MTT assay
For measuring the cell viability after ORF3 protein expression, PK-
15 cells or H1299 cells were cultured in 96-well plates at a density of
1×104 cells/well and transfected with the pEGFP N1 vector or pEGFP
N1 vector containing the full-length or deletion constructs of the
ORF3. Thirty-six hours after the transfection, the cultures were
incubated with 0.5 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide tetrazole) solution for 4 h at 37 °C then
solubilized in 150 μl dimethyl sulfoxide (DMSO). Nontransfected cells
were used as the baseline for the viability of the cells. The viable cells
convert the MTT into purple-colored insoluble formazan, which is
solubilized by DMSO. The optical density of the samples was
measured at 490 nm and data expressed as mean percentage of cell
survival in two individual experiments done in triplicates (±SD).
Flowcytometry
For the measuring the apoptotic cells after ORF3 protein
expression, PK-15 cells were cultured in 60-mm tissue culture dishes
and transfected with the pEGFP N1 vector or pEGFP N1 vector
containing the full-length or deletion constructs of the ORF3. Thirty-
six hours after the transfection, ﬂoating and trypsin-detached cells
were pooled andwashed twice with ice-cold PBS and ﬁxed in 70% cold
ethanol and then washed twice in PBS. After centrifugation, the cell
pellets were stained PBS–propidium iodide (50 μg/ml) and RNase A
(100 μg/ml) for 45 min. DNA content of PK-15 cells was analyzed byﬂuorescence-activated cell sorting (FACS Calibur; Becton Dickinson).
At least 10,000 events were analyzed, and the percentage of cell in the
sub-G0/G1 population was calculated. Aggregates of cell debris at the
origin of the FSC/SSC histogram were excluded from the analysis of
sub-G0/G1 cells. In each experiment, mock-infected PK-15 cells were
used as controls and compared with transfected cells.
In vitro ubiquitination assay
Ubiquitination assays were carried out by adding MBP-Pirh2
(1 μg), rabbit E1 (100 ng, Calbiochem), UbcH5b (E2) (200 ng,
Calbiochem), His-tagged ubiquitin (4 μg), GST-p53 (1 μg), MBP-ORF3
(1 μg), and 10 μl of BL-21 bacterial lysate in ubiquitination buffer
(50 mM Tris–HCl [pH 7.4], 2 mM ATP, 5 mMMgCl, 2 mM DTT, 30 mM
creatine phosphate, and 0.05 mg/ml creatine phosphokinase) to a
ﬁnal volume of 150 μl. The reactionswere incubated at 30 °C for 2 h. At
the end of the incubation, the volume was made up to 1 ml and the
GST-p53 was pulled down using glutathione-sepharose beads (GE
Amersham). The beads were then boiled in SDS loading buffer at 95 °C
for 5 min, and the supernatant was analyzed by Western blotting and
probing with anti-His monoclonal antibody (Covance) or anit-p53
guinea pig polyclonal antibody.Acknowledgments
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